U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07518160) titled 'JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study' on April 01.
Brief Summary: This is a Phase II study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of JS212 in combination with JS111 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations who have progressed after prior EGFR-TKI therapy.
The study consists of two parts: a dose-escalation phase followed by an expansion phase. Approximately 30 participants will be enrolled. The dose-escalation phase will explore the safety and tolerability of escalating doses of JS212 in combina...